MDA
MDA Space Ltd
MDA trails on the overall score without a compensating advantage in the available component scores.
MSFT
Microsoft Corporation
MSFT has the edge over MDA overall, supported by stronger fundamentals and lower modeled downside.
MDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Strong |
MDA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $29.16 | — |
| Cheap | 49x | $27.91 | -4.3% |
| Fair | 51x | $28.95 | -0.7% |
| Current | 51x | $29.16 | — |
| Expensive | 57x | $32.29 | +11% |
Historical ranges are pointers, not guarantees.
MDA has the edge over MSFT in the historical PE scenario, which offers more potential upside but is not a forecast.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
MDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for MDA, but weaker profitability. However, they disagree widely on these estimates.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
MSFT has the edge over MDA on the outlook, with more favorable profitability expectations.
MDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.06 | +85% |
| Q2 2026 | $0.57 | -14% |
| Q1 2026 | $0.59 | +3.5% |
| Q4 2025 | $0.61 | +30% |
| Q3 2025 | $0.61 | +49% |
| Q2 2025 | $0.66 | +128% |
| Q1 2025 | $0.57 | +104% |
| Q4 2024 | $0.47 | +57% |
| Q3 2024 | $0.41 | +52% |
MDA earned $0.57 per share over the past year, down 14% from the year before.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT's earnings per share have climbed steadily: $19.15 over the past year, up 36% from the year before, and higher year over year for 14 quarters in a row.
MDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $351M | +28% |
| Q1 2026 | $333.7M | +37% |
| Q4 2025 | $363.4M | +51% |
| Q3 2025 | $294.2M | +41% |
| Q2 2025 | $274.2M | +55% |
| Q1 2025 | $243.9M | +58% |
| Q4 2024 | $240.9M | +56% |
| Q3 2024 | $208.7M | +39% |
MDA has the edge over MSFT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 4.5% | -5.8 points |
| Q1 2026 | 7% | -3.1 points |
| Q4 2025 | 6.4% | +0.3 points |
| Q3 2025 | 3.9% | -5 points |
| Q2 2025 | 10% | +5.7 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 6.1% | +5.3 points |
| Q3 2024 | 8.9% | +4 points |
MDA's operating margin was 4.5% last quarter, down 5.8 points from the same quarter a year ago.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT's revenue has grown year over year every quarter since late 2020: $92.3B last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over MDA on profitability, with a higher operating margin.
MDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$102.4M | -2464% |
| Q1 2026 | -$4.5M | -102% |
| Q4 2025 | $11.7M | -95% |
| Q3 2025 | -$12.2M | -107% |
| Q2 2025 | $4.3M | -95% |
| Q1 2025 | $205.3M | +$207M |
| Q4 2024 | $230.2M | +$297M |
| Q3 2024 | $164.1M | +$213.5M |
MDA's free cash flow was −$107M over the past year, against $604M the year before.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT has the edge over MDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +9.8M shares |
| 1 year | +11% | +14.5M shares |
| 3 years | +19% | +22.3M shares |
| 5 years | +20% | +23.8M shares |
MDA has 143M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDA hasn't bought back shares in the past year.
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has the edge over MDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
MDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
| Q3 2024 | 1.7x | Healthy |
MDA has the edge over MSFT on leverage, with a lower net debt burden relative to earnings.
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
MDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 22.8 | Neutral |
MDA's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
MDA PE vs Technology Sector
| Metric | MDA | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 28x | 84% above |
| PE % | 58 | 18 | 40 pts above |
MDA is trading at 51x earnings, a 84% premium to the Technology sector's median of 28x, though its earnings don't support one.
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT has the edge over MDA on valuation relative to its sector.
MDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.4% above |
| 20 week MA | $30.7 | 4.9% below |
MSFT has stronger trend alignment. MDA is above 1 of 2 weekly averages versus MSFT above 4 of 5.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT's trend is up, with a small recent dip: it's below only its 8-week average, and 27% above its 200-week average.
MDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $29.1 | $29.2 | +0.1% |
It's roughly flat so far in 2026.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has the edge over MDA on returns for 2026, with the stronger performance.